B-hCB1 mice
C57BL/6-Cnr1tm1(CNR1)Bcgen/Bcgen • 110943

B-hCB1 mice

Catalog Number
110943
Strain Name
C57BL/6-Cnr1tm1(CNR1)Bcgen/Bcgen
Strain Background
C57BL/6
NCBI gene ID
1268 (Human)
Aliases
CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR

このページで

  • Description
  • Phenotypic analysis
  • Efficacy

ポスター

すべて表示

    出版物

      Description
      • CB1: A key receptor in the endocannabinoid system. 
      • Gene Information: Cannabinoid receptor 1 (CNR1) is a protein-coding gene located on chromosome 6q15 in humans. It encodes cannabinoid receptor type 1 (CB1), a G protein-coupled receptor (GPCR). 
      • Protein Expression: CB1 is widely expressed in the central nervous system, particularly in brain regions involved in appetite regulation, reward, memory, cognition, and pain processing. Peripheral expression is also present in tissues such as adipose tissue, liver, skeletal muscle, and the gastrointestinal tract, where CB1 signaling contributes to energy balance, lipid metabolism, and glucose homeostasis. 
      • Signaling Pathway: CB1 is primarily coupled to Gi/o proteins. Activation by endogenous ligands, including anandamide (AEA) and 2-arachidonoylglycerol (2-AG), can inhibit adenylyl cyclase, reduce intracellular cAMP levels, and modulate ion channels and neurotransmitter release. Through central and peripheral signaling, CB1 contributes to the regulation of appetite, energy balance, and metabolic homeostasis. 
      • Therapeutic Targeting: CB1 is an established pharmacological target under investigation for obesity and related metabolic disorders. Therapeutic strategies include small-molecule antagonists and inverse agonists, neutral antagonists, peripherally restricted CB1 blockers, and allosteric modulators.
      Human CNR1 mRNA Expression Analysis in CB1 Humanized Mice
      • Mouse Cnr1  mRNA was detectable only in cerebellum and brain tissue of wild-type C57BL/6JNifdc mice.
      • Human CNR1  mRNA was detectable only in cerebellum and brain tissue of homozygous CB1 humanized mice, but not in wild-type mice.

      Strain specific analysis of CNR1  mRNA expression in wild-type C57BL/6JNifdc mice and homozygous CB1 humanized mice by RT-PCR. Cerebellum and brain tissue were collected from wild-type C57BL/6JNifdc mice (+/+) and homozygous B-hCB1 mice (H/H). Mouse Cnr1  mRNA was detectable only in wild-type C57BL/6JNifdc mice. Human CNR1  mRNA was detectable only in homozygous B-hCB1 mice, but not in wild-type C57BL/6JNifdc mice.

      Human CB1 Protein Expression Analysis in Brain Tissue of CB1 Humanized Mice

      Mouse and human CB1 were detectable in wild-type C57BL/6JNifdc mice and homozygous CB1 humanized mice.

      Strain specific CB1 expression analysis in wild-type C57BL/6JNifdc mice and homozygous CB1 humanized mice by western blot. Cerebellum and brain tissue were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hCB1 mice (H/H) and analyzed by western blot with anti-CB1 antibody (Thermo Fisher, PA5-18427) which was cross reactive between mouse and human. Mouse and human CB1 were detectable in wild-type mice and homozygous B-hCB1 mice.

      In Vivo Efficacy Evaluation in DIO CB1 Humanized Mice
      • The CB1 antagonist and dulaglutide can significantly reduce body weight in diet-induced obesity(DIO) in CB1 humanized mice

      Body weight in DIO CB1 humanized mice. Homozygous B-hCB1 mice (male, n=30) were randomly assigned to two groups based on body weight: Group A (n = 8), fed a standard diet (STD), and Group B (n = 22), fed a high-fat diet (HFD). After 12 weeks of HFD feeding to induce DIO, the mice in Group B were randomly divided into three groups (G2, G3, and G4) and administered vehicle, an antagonist, or dulaglutide, respectively (n = 7–8 per group). (A) The schematic diagram of experimental processing. (B) Body weight after 12 weeks of DIO. (C-D) Body weight and weight changes in each group after treatment. As shown in Figure B, body weight was significantly higher in the HFD group than in the STD group, indicating that HFD feeding successfully induced obesity in B-hCB1 mice. As shown in Figures C and D, treatment with CB1 antagonists or dulaglutide significantly reduced body weight compared with the HFD vehicle group. Values are expressed as mean ± SEM.

      • The CB1 antagonist and dulaglutide reduced blood glucose and improved glucose tolerance in DIO CB1 humanized mice.

      The CB1 antagonist and dulaglutide improved glucose homeostasis in DIO CB1 humanized mice. (A) Random blood glucose during treatment. (B) Fasting blood glucose on Day 27 post-treatment. (C-D) Glucose tolerance test. As shown in the figure, the CB1 antagonist and dulaglutide can reduce random blood glucose and fasting blood glucose and improve glucose tolerance in DIO B-hCB1 mice. Values are expressed as mean ± SEM.

      • The CB1 antagonist and dulaglutide reduced lipid metabolism in DIO CB1 humanized mice.

      The CB1 antagonist and dulaglutide improved lipid metabolism in DIO CB1 humanized mice. (A) TG in liver. (B) TC in liver. (C) TG in blood. (D) TC in blood. As shown in the figure, the CB1 antagonist and dulaglutide can reduce the level of TG in liver and TC in blood. Values are expressed as mean ± SEM.

      • The CB1 antagonist and dulaglutide reduced liver damage in DIO CB1 humanized mice.

      The CB1 antagonist and dulaglutide reduced liver damage in DIO CB1 humanized mice.(A) Representative H&E-stained liver images (representative dataset from n = 7-8 per group). (B) Statistical analysis of total histological score for hepatocellular steatosis, lobular inflammation and ballooning degeneration. Values are expressed as mean ± SD.

      * When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hCB1 mice] (Cat# 110943) was purchased from Biocytogen.